| Literature DB >> 25443626 |
Dedee F Murrell1, Branka Marinovic2, Frederic Caux3, Catherine Prost4, Razzaque Ahmed5, Katarzyna Wozniak6, Masayuki Amagai7, Johann Bauer8, Stefan Beissert9, Luca Borradori10, Donna Culton11, Janet A Fairley12, David Fivenson13, Marcel F Jonkman14, M Peter Marinkovich15, David Woodley16, John Zone17, Valeria Aoki18, Philippe Bernard19, Leena Bruckner-Tuderman20, Giuseppe Cianchini21, Vanessa Venning22, Luis Diaz11, Rudiger Eming23, Sergei A Grando24, Russell P Hall25, Takashi Hashimoto26, Josep E Herrero-González27, Michael Hertl28, Pascal Joly29, Sarolta Karpati30, Jaehwan Kim31, Soo Chan Kim32, Neil J Korman33, Cezary Kowalewski6, Sang Eun Lee34, David R Rubenstein11, Eli Sprecher35, Kim Yancey36, Giovanna Zambruno37, Detlef Zillikens38, Serge Doan39, Benjamin S Daniel40, Victoria P Werth41.
Abstract
Mucous membrane pemphigoid encompasses a group of autoimmune bullous diseases with a similar phenotype characterized by subepithelial blisters, erosions, and scarring of mucous membranes, skin, or both. Although knowledge about autoimmune bullous disease is increasing, there is often a lack of clear definitions of disease, outcome measures, and therapeutic end points. With clearer definitions and outcome measures, it is possible to directly compare the results and data from various studies using meta-analyses. This consensus statement provides accurate and reproducible definitions for disease extent, activity, outcome measures, end points, and therapeutic response for mucous membrane pemphigoid and proposes a disease extent score, the Mucous Membrane Pemphigoid Disease Area Index.Entities:
Keywords: consensus; definitions; mucous membrane pemphigoid; outcome measures; severity score
Mesh：
Year: 2014 PMID： 25443626 DOI： 10.1016/j.jaad.2014.08.024
Source DB: PubMed Journal: J Am Acad Dermatol ISSN： 0190-9622 Impact factor: 11.527